Table 2.
Demographic and clinical characteristics
| Variables | All patients (n 205) |
AKI (n 173) |
No AKI (n 32) |
P value |
|---|---|---|---|---|
| Age at transplant in years | 8.0(0.3–21.0) | 8.0(0.3–21.0) | 8.4(0.7–20.6) | 0.81 |
| Median (range) | ||||
| Gender | 0.03 | |||
| Male | 125(61%) | 100(80%) | 25(20%) | |
| Female | 80(39%) | 73(91%) | 7(9%) | |
| Race | < 0.01 | |||
| Caucasian | 154(75%) | 132(86%) | 22(14%) | |
| African American | 15(7%) | 15(100%) | 0 | |
| Native American | 3(2%) | 1(33%) | 2(67%) | |
| Asian | 11(5%) | 7(64%) | 4(36%) | |
| Other | 10(5%) | 7(70%) | 3(30%) | |
| Unknown | 12(6%) | 11(92%) | 1(8%) | |
| Indication for HSCT | 0.60 | |||
| Malignant | 113(55%) | 94(83%) | 19(17%) | |
| Nonmalignant | 92(45%) | 79(86%) | 13(14%) | |
| Conditioning Intensity | 0.91 | |||
| Myeloablative | 149(73%) | 126(85%) | 23(15%) | |
| Reduced intensity | 56(27%) | 47(84%) | 9(16%) | |
| Conditioning regimen | ||||
| Allogeneic recipients | 0.81 | |||
| Cyclophos/TBI based | 91(53%) | 79 (87%) | 12 (13%) | |
| Busulfan/Cyclophos based | 43 (25%) | 39 (91%) | 4 (9%) | |
| Melphalan based | 10 (6%) | 9 (90%) | 1 (10%) | |
| Cyclophos based | 8 (5%) | 7 (88%) | 1 (12%) | |
| Carboplatin/etoposide | 0 (0%) | 0 (0%) | 0 (0%) | |
| Busulfan/Melphalan based | 7 (4%) | 7 (100%) | 0 (0%) | |
| Others | 15 (9%) | 12 (80%) | 3 (20%) | |
| Autologous recipients | 0.04 | |||
| Cyclophos/TBI based | 2 (6%) | 2 (100%) | 0 (0%) | |
| Busulfan/Cyclophos based | 0 (0%) | 0 (0%) | 0 (0%) | |
| Melphalan based | 7 (2%) | 2 (29%) | 5 (71%) | |
| Cyclophos based | 6 (2%) | 6(100%) | 0 (0%) | |
| Carboplatin/etoposide | 4 (1%) | 4(100%) | 0 (0%) | |
| Busulfan/Melphalan based | 8 (3%) | 4(50%) | 4(50%) | |
| Others | 4 (1%) | 2(50%) | 2(50%) | |
| Use of TBI | 0.25 | |||
| Yes | 96(47%) | 84(88%) | 12(12%) | |
| No | 109(53%) | 89(82%) | 20(18%) | |
| Stem Cell Source | <0.01 | |||
| Bone Marrow | 79(39%) | 68(86%) | 11(14%) | |
| Peripheral blood | 34(17%) | 22(65%) | 12(35%) | |
| Umbilical cord | 92(45%) | 83(90%) | 9(10%) | |
| Donor Source | 0.02 | |||
| Autologous | ||||
| MRD | 31(15%) | 20(65%) | 11(35%) | |
| MMRD | 35(17%) | 31(89%) | 4(11%) | |
| MURD | 6(3%) | 5(83%) | 1(17%) | |
| MMURD | 82(40%) | 74(90%) | 8(10%) | |
| 51(25%) | 43(84%) | 8(16%) | ||
| aGVHD (grades 3–4) | 0.98 | |||
| Yes | 13(6%) | 11(85%) | 2(15%) | |
| No | 192(94%) | 162(84%) | 30(16%) | |
| VOD | 0.04 | |||
| Yes | 21 (10%) | 21(100%) | 0 | |
| No | 184 (90%) | 152(83%) | 32(17%) |
Abbreviation: AKI – acute kidney injury; TBI- total body irradiation; MRD – matched related donor; MMRD – mismatched related donor; MURD – matched unrelated donor; MMURD – mismatched unrelated donor; aGVHD – acute graft versus host disease; VOD – veno - occlusive disease; HSCT – hematopoietic stem cell transplant; cyclophos - cyclophosphamide